[HTML][HTML] A monoclonal thyroid-stimulating antibody

T Ando, R Latif, A Pritsker, T Moran… - The Journal of …, 2002 - Am Soc Clin Investig
T Ando, R Latif, A Pritsker, T Moran, Y Nagayama, TF Davies
The Journal of clinical investigation, 2002Am Soc Clin Investig
The thyrotropin receptor, also known as the thyroid-stimulating hormone receptor (TSHR), is
the primary antigen of Graves disease. Stimulating TSHR antibodies are the cause of thyroid
overstimulation and were originally called long-acting thyroid stimulators due to their
prolonged action. Here we report the successful cloning and characterization of a
monoclonal antibody (MS-1) with TSHR-stimulating activity. The thyroid-stimulating activity
of MS-1 was evident at IgG concentrations as low as 20 ng/ml. MS-1 also competed for …
The thyrotropin receptor, also known as the thyroid-stimulating hormone receptor (TSHR), is the primary antigen of Graves disease. Stimulating TSHR antibodies are the cause of thyroid overstimulation and were originally called long-acting thyroid stimulators due to their prolonged action. Here we report the successful cloning and characterization of a monoclonal antibody (MS-1) with TSHR-stimulating activity. The thyroid-stimulating activity of MS-1 was evident at IgG concentrations as low as 20 ng/ml. MS-1 also competed for radiolabeled TSH binding to the native TSHR and was able to compete for TSH-induced stimulation. MS-1 recognized a conformational epitope within the TSHR α (or A) subunit but excluding the receptor cleavage region. Using an assay measuring loss of antibody recognition after cleavage we demonstrated that MS-1, in contrast to TSH, was unable to enhance TSHR posttranslational cleavage. Since receptor cleavage is followed by α subunit shedding and receptor degradation, the functional half-life of the receptor may be extended. The isolation and characterization of MS-1 provides a novel explanation for the prolonged thyroid stimulation in this disease which may be secondary to the lack of receptor cleavage in addition to the prolonged half-life of IgG itself.
The Journal of Clinical Investigation